medigraphic.com
ISSN 1561-2996 (Electronic)
ISSN 0864-0289 (Print)

2022, Number 4

<< Back Next >>

Rev Cubana Hematol Inmunol Hemoter 2022; 38 (4)

Outcome of autologous stem cell transplantation in patients with multiple myeloma

Roque GW, Valladares UY, Fernández ÁJD, Jaime FJC, Sarduy SS

Language: Spanish
References: 20
Page: 1-13
PDF size: 936.59 Kb.


ABSTRACT

Introduction: Multiple myeloma is a neoplasm characterized by the presence of a plasmatic cells clone; accounts for 1 % of cancers, and approximately 10 % of hematologic malignancies. High dose chemotherapy followed by autologous stem cell transplantation remains a safe option in selected patients.
Objective: To analyze the results of autologous stem cell transplantation from peripheral blood in patients with multiple myeloma.
Methods: A descriptive, longitudinal, ambispective study. The universe was by 14 patients (13 of them were finally included), with diagnosis of multiple myeloma treated with autologous stem cell transplantation from peripheral blood at Institute of Hematology and Immunology of Havana from January 2014 to December 2019.
Results: The median age of the patient was 53.9±5.6 years, with predominance of female sex. More frequents complications were infections and mucositis. A year overall survival was 100 % and 80 % at five years. Progression free survival at one and five years was 83% and 73%, respectively.
Conclusions: The autologous stem cell transplantation in multiple myeloma patients increase complete responses, overall survival and progression free survival and is well accepted without severe complications.


REFERENCES

  1. Munshi NC, Jagannath S. Plasma cell neoplasms. In: Hoffman R, Weitz JI, Benz EJ, Anastasi J, Silberstein LE, Salama ME, et al. eds. Hematology, Basic Principles and Practice, 7th ed. Philadelphia: Elsevier; 2018. p. 1381 -418.

  2. Rajkumar VS. Multiple Myeloma: every year a new standard? Hematol Oncol. 2019;37 (Suppl 1):62-5. DOI: https://10.1002/hon.25862.

  3. Ludwig H, Novis Durie S, Meckl A, Hinke A, Durie B. Multiple Myeloma Incidence and Mortality Around the Globe; Interrelations Between Health Access and Quality, Economic Resources, and Patient Empowerment. Oncologist. 2020. 25(9):e1406-13. DOI: https://10.1634/theoncologist.2020-01413.

  4. Da Silva-FerreiraI K, Rafael-Maciel JF, De Souza Rego Pinto Carvalho DP, Campos de Azevedo I, Fortes-Vitor A, Ferreira-Júnior MA. Clinical characterization and survival of patients with multiple myeloma in a state of northeast brazilian. Rev Cubana Hematol Inmunol Hemoter. 2017; 33(2)

  5. Gerecke C, Fuhrmann S, Strifler S, Schmidt-Hieber M, Einsele H, Knop S. The diagnosis and treatment of multiple myeloma. Dtsch Arztebl Int. 2016;113(27-28):470-6. DOI: https://10.3238/arztebl.2016.04705.

  6. Michels TC, Petersen KE. Multiple Myeloma: Diagnosis and treatment. Am Fam Physician. 2017;15;95(6):373-83.

  7. Huang TC, Huang SY, Yao M, Lin CY, Hwang WL, Gau JP, et al. Autologous stem cell transplantation in multiple myeloma: Posttransplant outcomes of Taiwan Blood and Marrow Transplantation Registry. J Formos Med Assoc. 2019;118:471-80. DOI: https://10.1016/j.jfma.2018.07.0207.

  8. Rajkumar SV, Kumar S. Multiple myeloma current treatment algorithms. Blood Cancer J. 2020 Sep 28;10(9):94. DOI: https://10.1038/s41408-020-00359-28.

  9. Jaramillo F, Useche E, García J, Rosales M, Manzi E, Estacio M, et al. Trasplante autólogo de células madre hematopoyéticas en pacientes con diagnóstico de mieloma múltiple, experiencia en 9 años. Rev Colomb Cancerol. 2018;22(4):138-42 DOI: https://10.1016/j.rccan.2018.10.0019.

  10. Hari P. Recent advances in understanding multiple myeloma. Hematol Oncol Stem Cell Ther. 2017;10(4):267-71. DOI: https://10.1016/j.hemonc.2017.05.00510.

  11. D'Souza A, Lee S, Zhu X, Pasquini M. Current use and trends in hematopoietic cell transplantation in the United States. Biol Blood Marrow Transplant. 2017;23(9):1417-21. DOI: https://10.1016/j.bbmt.2020.04.01311.

  12. Majhail NS, Farnia SH, Carpenter PA, Champlin RE, Crawford S, Marks DI, et al. Indications for Autologous and Allogeneic Hematopoietic Cell Transplantation: Guidelines from the American Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2015; 21(11):1863-9. DOI: https://10.1016/j.bbmt.2015.07.03212.

  13. D Souza A, Fretham C, Lee SJ, Arora M, Brunner J, Chhabra S, et al. Current Use of and Trends in Hematopoietic Cell Transplantation in the United States. Biol Blood Marrow Transplant. 2020;26(8):e177-82. DOI: https://10.1016/j.bbmt.2020.04.01313.

  14. Malhotra P, Yanamandra U, Khadwal A, Prakash G, Lad D, Law AD, et al. Autologous stem cell transplantation for multiple myeloma: Single center experience from North India. Indian J Hematol Blood Transfus. 2018; 34(2):261-7. DOI: https://10.1007/s12288-017-0876-y14.

  15. Hernández-Cruz C, Carnot-Uria J, Diego-de la Campa J, Muñío Perurena J, Pardo-Ramírez IK, García-García A. Trasplante de progenitores hematopoyéticos autólogo en gammapatías monoclonales: primeros resultados del Hospital "Hermanos Ameijeiras". Rev Cubana Hematol Inmunol Hemoter. 2019;35(4):a_1092.

  16. White L, Ybarra M. Neutropenic fever. Hematol Oncol Clin North Am. 2017;31(6):981-93. DOI: https://10.1007/978-3-030-21859-1_816.

  17. Sánchez L, Sylvester M, Parrondo R, Mariotti V, Anderson Eloy J, Chang VT. In-hospital mortality and post-transplantation complications in elderly multiple myeloma patients undergoing autologous hematopoietic stem cell transplantation: A population-based study. Biol Blood Marrow Transplant. 2017 Jul;23(7):1203-7. DOI: https://10.1016/j.bbmt.2017.03.01217.

  18. Laheij AMGA, Raber-Durlacher JE, Koppelmans RGA, Huysmans MCDNJM, Potting C, van Leeuwen SJM, et al. Microbial changes in relation to oral mucositis in autologous hematopoietic stem cell transplantation recipients. Sci Rep. 2019;9:16929. DOI: https://10.1038/s41598-019-53073-w18.

  19. Colunga-Pedraza PR, Colunga-Pedraza JE, Bugarin-Estrada E, Yáñez-Reyes JM, Gutiérrez-Aguirre CH. Complicaciones infecciosas posteriores al trasplante de progenitores hematopoyéticos. Hematol Méx. 2018;19(4):215-30.

  20. Auner HW, Iacobelli S, Sbianchi G, Knol-Bout C, Blaise D, Russell NH, et al. Melphalan 140 mg/m2 or 200 mg/m2 for autologous transplantation in myeloma: results from the Collaboration to Collect Autologous Transplant Outcomes in Lymphoma and Myeloma (CALM) study. A report by the EBMT Chronic Malignancies Working Party. Haematologica. 2018;.103(3): 514-21. DOI: https://10.3324/haematol.2017.18133920.




2020     |     www.medigraphic.com